These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25963872)

  • 1. The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?
    Hellard M; Scott N
    Addiction; 2015 Jun; 110(6):984-5. PubMed ID: 25963872
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to end treatment restrictions for people with hepatitis C who inject drugs.
    Rosenthal ES; Kattakuzhy S; Kottilil S
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):142-143. PubMed ID: 29310927
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to: "Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C".
    EASL Recommendations for Treatment of Hepatitis C 2016 Panel. Electronic address: easloffice@easloffice.eu
    J Hepatol; 2017 May; 66(5):1103. PubMed ID: 28167321
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus treatment as prevention in people who inject drugs.
    White PJ; Abubakar I
    Lancet Infect Dis; 2018 Apr; 18(4):379. PubMed ID: 29582763
    [No Abstract]   [Full Text] [Related]  

  • 5. Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ;
    J Hepatol; 2017 May; 66(5):1101-1103. PubMed ID: 28167323
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis C virus transmission in people who inject drugs: swabs may not be the main culprit.
    Maher L; Wand H
    J Infect Dis; 2012 Jun; 205(12):1892; author reply 1892-3. PubMed ID: 22535997
    [No Abstract]   [Full Text] [Related]  

  • 7. Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs.
    Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ;
    Int J Drug Policy; 2015 Nov; 26(11):1039-40. PubMed ID: 26254496
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C virus infection in people who inject drugs in Africa.
    Kim JU; Mohamed Z; Mbwambo J; Rwegasha J; Lemoine M
    Lancet Infect Dis; 2020 Mar; 20(3):283-284. PubMed ID: 32112758
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus infection in people who inject drugs in Africa.
    Shah R; Boucheron P; Mandaliya K; Kattamaiyo A; Chevaliez S; Shimakawa Y; Songok E; Lemoine M
    Lancet Infect Dis; 2020 Mar; 20(3):282-283. PubMed ID: 32112757
    [No Abstract]   [Full Text] [Related]  

  • 10. Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
    Hutin YJ; Wiktor SZ
    Gut; 2017 Dec; 66(12):2052-2053. PubMed ID: 27566128
    [No Abstract]   [Full Text] [Related]  

  • 11. Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.
    Smith JM; Rich JD
    Hepatology; 2017 Jun; 65(6):2129. PubMed ID: 28108982
    [No Abstract]   [Full Text] [Related]  

  • 12. How to eliminate HCV in people who inject drugs in the USA.
    Dahari H; Boodram B
    Lancet Infect Dis; 2018 Feb; 18(2):134-135. PubMed ID: 29153267
    [No Abstract]   [Full Text] [Related]  

  • 13. Agent, host, and environment: hepatitis C virus in people who inject drugs.
    Hagan H
    J Infect Dis; 2011 Dec; 204(12):1819-21. PubMed ID: 22013223
    [No Abstract]   [Full Text] [Related]  

  • 14. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.
    Leask JD; Dillon JF
    Aliment Pharmacol Ther; 2016 Jul; 44(2):145-56. PubMed ID: 27199103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
    Wade AJ; Macdonald DM; Doyle JS; Gordon A; Roberts SK; Thompson AJ; Hellard ME
    PLoS One; 2015; 10(11):e0142770. PubMed ID: 26562516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications of immune protection from hepatitis C infection.
    Aitken CK; Bowden S; Hellard M; Crofts N
    J Urban Health; 2004 Mar; 81(1):58-60. PubMed ID: 15047784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
    Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y
    Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study.
    Goutzamanis S; Doyle JS; Thompson A; Dietze P; Hellard M; Higgs P;
    BMC Infect Dis; 2018 Apr; 18(1):151. PubMed ID: 29609552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    Falade-Nwulia O; Sulkowski M
    J Hepatol; 2017 Feb; 66(2):267-269. PubMed ID: 27816493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.